M802
HER2-Positive Solid Tumors
Wuhan YZY Biopharma Co., Ltd.Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
7 Active assets in the HER2-Positive Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Iambic Therapeutics, Inc | Phase 1 | CC |
TRASTUZUMAB Iambic Therapeutics, Inc | Phase 1 | CC |
Zanidatamab Iambic Therapeutics, Inc | Phase 1 | CC |
iam1363 Iambic Therapeutics, Inc | Phase 1 | CC |
Carboplatin Iambic Therapeutics, Inc | Phase 1 | CC |
View all 10 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →